Methods and compositions for the prevention of and treatment of infections utilizing chitosan-derivative compounds
The present invention is directed to the treatment and prevention of nosocomial infections or MRSA infections utilizing soluble chitosan or chitosan derivative compounds. These chitosan-derivative compounds, e.g., chitosan-arginine and chitosan-acid amines, exhibit bactericidal activity against bacterial pathogens, e.g., drug resistant bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA).
1. A method of treating a methicillin-resistant Staphylococcus aureus (MRSA) infection or reducing MRSA load, the method comprising:
administering, to a subject who has a MRSA infection, an effective amount of derivatized chitosan of formula (I):
wherein:
n is an integer between 20 and 6000;
each R 1 is independently selected for each occurrence from hydrogen, acetyl, and a group of formula (II):
at least 25% of R 1 substituents are H, at least 1% of R 1 substituents are acetyl, and 4-30% of R 1 substituents are a group of formula (II); and
the derivatized chitosan of formula (I) is administered at a concentration of 25-100 ppm,
thereby treating the MRSA infection or reducing MRSA load.
2. The method of claim 1 , wherein the subject is a human or an animal.
3. The method of claim 1 , wherein the MRSA infection has previously been treated with an antibiotic without a soluble chitosan or derivatized chitosan.
4. The method of claim 1 , wherein the subject has one or more symptoms selected from a group consisting of: a red, swollen and painful area on the skin, drainage of pus or other fluids from the infected site, fever, skin abscess, warmth around the infected area, chest pain, chills, fatigue, fever, malaise, headache, muscle aches, rash, wound, skin breach, and/or shortness of breath.
5. The method of claim 1 , wherein the soluble chitosan or derivatized chitosan is administered topically, enterally or parenterally.
6. The method of claim 1 , wherein the soluble chitosan or derivatized chitosan is administered by inhalation spray.
7. The method of claim 1 , wherein the soluble chitosan or derivatized chitosan is not administered in combination with a second therapy.
8. The method of claim 1 , wherein the MRSA is selected from EMRSA15 strain, EMRSA16 strain, CC8 strain designated ST8:USA300, ST8:USA400 strain, ST8:USA500 strain, ST59:USA1000 strain, ST59 strain, ST80 strain, ST93 strain, MW-2 strain, MNHO strain, or clinical isolates from a hospital.
9. The method of claim 1 , wherein the soluble chitosan or derivatized chitosan reduces MRSA load in the subject by at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, 99, 99.9, or 99.99%, compared to the MRSA load in the subject before treatment with the soluble chitosan or derivatized chitosan.
10. The method of claim 1 , wherein between 25-95% of R 1 substituents are hydrogen.
11. The method of claim 1 , wherein between 55-90% of R 1 substituents are hydrogen.
12. The method of claim 1 , wherein between 4-20% of R 1 substituents are acetyl.
13. The method of claim 1 , wherein 55-90% of R 1 substituents are hydrogen, 4-20% of R 1 substituents are acetyl, 4-30% of R 1 substituents are a group of formula (II).
14. The method of claim 1 , wherein the molecular weight of the derivatized chitosan is between 5,000 and 1,000,000 Da.
15. The method of claim 1 , wherein the molecular weight of the derivatized chitosan is between 5,000 and 350,000Da.
16. The method of claim 1 , wherein the molecular weight of the derivatized chitosan is between 5,000 and 60,000 Da.
17. The method of claim 1 , wherein the molecular weight of the derivatized chitosan is between 5,000 and 35,000 Da.
18. The method of claim 1 , wherein the derivatized chitosan is soluble in aqueous solution between pH 6.8 and pH 7.4.
19. The method of claim 1 , wherein the derivatized chitosan is substantially free of other impurities.